EUVIMEDEUVIMED entdecken
Multizentrische Studie

Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects

Aaron K Wong iD, Pal Klepstad, Andrew A Somogyi, Sara Vogrin, Justin Rubio, Brian Le, Jennifer Philip iD

Journal of Palliative Medicine · 01.11.2024 · 27 (11) · 1512-1521

DOI: 10.1089/jpm.2024.0112 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Palliative Medicine, erschienen am 01.11.2024. Verfasst von Aaron K Wong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Catechol O-Methyltransferase, Cancer Pain, Analgesics, Opioid, Receptors, Opioid, mu. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The influence of pharmacogenomics on opioid response, particularly with COMT (rs4680) and OPRM1 (rs1799971) variants, has been studied individually and in combination. However, most studies are in a noncancer context and not all their possible variant combinations have been examined.

Objectives

This study examined COMT (rs4680) and OPRM1 (rs1799971), and their allele combinations, in advanced cancer to examine associations with pain scores, opioid dose, and adverse effects. Setting/Subjects: This multicenter prospective cohort study recruited patients receiving opioids for advanced cancer pain in Melbourne, Australia. Clinical data (demographics, opioids), validated instruments (pain and adverse effects), and blood (DNA) were collected. Descriptive analyses were used. Univariate and multivariate logistic regression analyses were used to evaluate associations between clinical outcomes (opioid dose, pain, adverse effects) and genotypes of interest.

Results

Fifty-four participants were recruited to the study. Those with COMT A allele required lower opioid doses [130 mg (interquartile range [IQR] 67.5,230) versus 180 mg (IQR 55,322.5), p = 0.047] and experienced greater adverse effects [sickness response aOR (adjusted odds ratio) 7.1 (95% CI 1.51,33.41), p = 0.01]. Those with the COMT GG/OPRM1 G allele combination required higher opioid doses [322.5 mg (IQR 264,360) versus 125 mg (65,225), (p = 0.04)]. Those with COMT AG/OPRM1 AA experienced higher average pain [aOR 1.55 (95% CI 1.03, 2.33), p = 0.04] and moderate-severe nausea [aOR 5.47 (95% CI 1.35, 22.21), p = 0.02] but reduced drowsiness [aOR 0.25 (95% CI 0.06, 1.02), p = 0.05].

Conclusions

Patients with cancer with the COMT alternate (A) allele have greater sickness response adverse effects, which may be responsible for the lower opioid doses observed. Significant results of two new COMT/OPRM1 genotype combinations are presented that have not previously been studied, with plausible phenotype descriptions suggested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catechol O-MethyltransferaseCancer PainAnalgesics, OpioidReceptors, Opioid, muHumansMaleFemaleMiddle AgedProspective StudiesAgedAustraliaCohort StudiesAdult

Stichwörter der Autor:innen

advanced canceropioidpalliative carepharmacogenetics

Substanzen

Catechol O-MethyltransferaseOPRM1 protein, humanAnalgesics, OpioidCOMT protein, humanReceptors, Opioid, mu

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • The Royal Melbourne Hospital, Parkville, Australia.
  • Department of Medicine, University of Melbourne, Fitzroy, Australia.
  • Department Intensive Care Medicine, St. Olavs University Hospital, Trondheim, Norway.
  • Discipline of Pharmacology, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
  • Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia.

ORCID-Profile: Aaron K Wong, Jennifer Philip

Zitieren

APA

Wong, A. K., Klepstad, P., Somogyi, A. A., Vogrin, S., Rubio, J., Le, B., & Philip, J. (2024). Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects. Journal of Palliative Medicine, 27(11), 1512-1521. https://doi.org/10.1089/jpm.2024.0112

Vancouver

Wong AK, Klepstad P, Somogyi AA, Vogrin S, Rubio J, Le B, et al. Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects. Journal of Palliative Medicine. 2024;27(11):1512-1521. doi:10.1089/jpm.2024.0112

BibTeX
@article{Wong2024,
  author = {Wong, Aaron K and Klepstad, Pal and Somogyi, Andrew A and Vogrin, Sara and Rubio, Justin and Le, Brian and Philip, Jennifer},
  title = {Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects},
  journal = {Journal of Palliative Medicine},
  year = {2024},
  volume = {27},
  number = {11},
  pages = {1512--1521},
  doi = {10.1089/jpm.2024.0112}
}
Kostenlos starten →